|
1
|
Lv C, Li F, Li X, Tian Y, Zhang Y, Sheng
X, Song Y, Meng Q, Yuan S, Luan L, et al: MiR-31 promotes mammary
stem cell expansion and breast tumorigenesis by suppressing Wnt
signaling antagonists. Nat Commun. 8:10362017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Russell JO and Monga SP: Wnt/β-catenin
signaling in liver development, homeostasis, and pathobiology. Annu
Rev Pathol. 13:351–378. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tammela T, Sanchez-Rivera FJ, Cetinbas NM,
Wu K, Joshi NS, Helenius K, Park Y, Azimi R, Kerper NR, Wesselhoeft
RA, et al: A Wnt-producing niche drives proliferative potential and
progression in lung adenocarcinoma. Nature. 545:355–359. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Arnold M, Sierra MS, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global patterns and trends in
colorectal cancer incidence and mortality. Gut. 66:683–691. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Suzuki H, Watkins DN, Jair KW, Schuebel
KE, Markowitz SD, Chen WD, Pretlow TP, Yang B, Akiyama Y, Van
Engeland M, et al: Epigenetic inactivation of SFRP genes allows
constitutive WNT signaling in colorectal cancer. Nat Genet.
36:417–422. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rattner A, Hsieh JC, Smallwood PM, Gilbert
DJ, Copeland NG, Jenkins NA and Nathans J: A family of secreted
proteins contains homology to the cysteine-rich ligand-binding
domain of frizzled receptors. Proc Natl Acad Sci USA. 94:2859–2863.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yu J, Xie Y, Li M, Zhou F, Zhong Z, Liu Y,
Wang F and Qi J: Association between SFRP promoter hypermethylation
and different types of cancer: A systematic review and
meta-analysis. Oncol Lett. 18:3481–3492. 2019.PubMed/NCBI
|
|
8
|
Qi J, Zhu YQ, Luo J and Tao WH:
Hypermethylation and expression regulation of secreted
frizzled-related protein genes in colorectal tumor. World J
Gastroenterol. 12:7113–7117. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Qi J and Zhu YQ: Targeting the most
upstream site of Wnt signaling pathway provides a strategic
advantage for therapy in colorectal cancer. Curr Drug Targets.
9:548–557. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Santanach A, Blanco E, Jiang H, Molloy KR,
Sansó M, LaCava J, Morey L and Di Croce L: The Polycomb group
protein CBX6 is an essential regulator of embryonic stem cell
identity. Nat Commun. 8:12352017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bracken AP and Helin K: Polycomb group
proteins: Navigators of lineage pathways led astray in cancer. Nat
Rev Cancer. 9:773–784. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kerppola TK: Polycomb group complexes-many
combinations, many functions. Trends Cell Biol. 19:692–704. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rush M, Appanah R, Lee S, Lam LL, Goyal P
and Lorincz MC: Targeting of EZH2 to a defined genomic site is
sufficient for recruitment of Dnmt3a but not de novo DNA
methylation. Epigenetics. 4:404–414. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Viré E, Brenner C, Deplus R, Blanchon L,
Fraga M, Didelot C, Morey L, Van Eynde A, Bernard D, Vanderwinden
JM, et al: The Polycomb group protein EZH2 directly controls DNA
methylation. Nature. 439:871–874. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chang CJ, Yang JY, Xia W, Chen CT, Xie X,
Chao CH, Woodward WA, Hsu JM, Hortobagyi GN and Hung MC: EZH2
promotes expansion of breast tumor initiating cells through
activation of RAF1-β-catenin signaling. Cancer Cell. 19:86–100.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Takawa M, Masuda K, Kunizaki M, Daigo Y,
Takagi K, Iwai Y, Cho HS, Toyokawa G, Yamane Y, Maejima K, et al:
Validation of the histone methyltransferase EZH2 as a therapeutic
target for various types of human cancer and as a prognostic
marker. Cancer Sci. 102:1298–1305. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lai AY and Wade PA: Cancer biology and
NuRD: A multifaceted chromatin remodelling complex. Nat Rev Cancer.
11:588–596. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Desai MA, Webb HD, Sinanan LM, Scarsdale
JN, Walavalkar NM, Ginder GD and Williams DC Jr: An intrinsically
disordered region of methyl-CpG binding domain protein 2 (MBD2)
recruits the histone deacetylase core of the NuRD complex. Nucleic
Acids Res. 43:3100–3113. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lee J, Lee MS, Jeoung DI, Kim YM and Lee
H: Promoter CpG-site methylation of the KAI1 metastasis suppressor
gene contributes to its epigenetic repression in prostate cancer.
Prostate. 77:350–360. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Huang WY, Hsu SD, Huang HY, Sun YM, Chou
CH, Weng SL and Huang HD: MethHC: A database of DNA methylation and
gene expression in human cancer. Nucleic Acids Res. 43((Database
Issue)): D856–D861. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhou FF, Xie W, Chen SQ, Wang XK, Liu Q,
Pan XK, Su F and Feng MH: SLC38A1 promotes proliferation and
migration of human colorectal cancer cells. J Huazhong Univ Sci
Technolog Med Sci. 37:30–36. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xie Y, Yu J, Wang F, Li M, Qiu X, Liu Y
and Qi J: ERCC6L promotes cell growth and invasion in human
colorectal cancer. Oncol Lett. 18:237–246. 2019.PubMed/NCBI
|
|
25
|
Zhou Z, Wang J, Han X, Zhou J and Linder
S: Up-regulation of human secreted frizzled homolog in apoptosis
and its down-regulation in breast tumors. Int J Cancer. 78:95–99.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Suzuki H, Gabrielson E, Chen W, Anbazhagan
R, van Engeland M, Weijenberg MP, Herman JG and Baylin SB: A
genomic screen for genes upregulated by demethylation and histone
deacetylase inhibition in human colorectal cancer. Nat Genet.
31:141–149. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wong SC, Lo SF, Lee KC, Yam JW, Chan JK
and Wendy Hsiao WL: Expression of frizzled-related protein and
Wnt-signalling molecules in invasive human breast tumours. J
Pathol. 196:145–153. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Vincan E and Barker N: The upstream
components of the Wnt signalling pathway in the dynamic EMT and MET
associated with colorectal cancer progression. Clin Exp Metastasis.
25:657–663. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu K, Xu C, Lei M, Yang A, Loppnau P,
Hughes TR and Min J: Structural basis for the ability of MBD
domains to bind methyl-CG and TG sites in DNA. J Biol Chem.
293:7344–7354. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Álvarez-Errico D, Vento-Tormo R, Sieweke M
and Ballestar E: Epigenetic control of myeloid cell
differentiation, identity and function. Nat Rev Immunol. 15:7–17.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wood KH, Johnson BS, Welsh SA, Lee JY, Cui
Y, Krizman E, Brodkin ES, Blendy JA, Robinson MB, Bartolomei MS and
Zhou Z: Tagging methyl-CpG-binding domain proteins reveals
different spatiotemporal expression and supports distinct
functions. Epigenomics. 8:455–473. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gunawan M, Venkatesan N, Loh JT, Wong JF,
Berger H, Neo WH, Li LY, La Win MK, Yau YH, Guo T, et al: The
methyltransferase Ezh2 controls cell adhesion and migration through
direct methylation of the extranuclear regulatory protein talin.
Nat Immunol. 16:505–516. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xia L, Zhu X, Zhang L, Xu Y, Chen G and
Luo J: EZH2 enhances expression of CCL5 to promote recruitment of
macrophages and invasion in lung cancer. Biotechnol Appl Biochem.
67:1011–1019. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
First EZH2 inhibitor approved-for rare
sarcoma. Cancer Discov. 10:333–334. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mohammad F, Weissmann S, Leblanc B, Pandey
DP, Højfeldt JW, Comet I, Zheng C, Johansen JV, Rapin N, Porse BT,
et al: EZH2 is a potential therapeutic target for H3K27M-mutant
pediatric gliomas. Nat Med. 23:483–492. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Comet I, Riising EM, Leblanc B and Helin
K: Maintaining cell identity: PRC2-mediated regulation of
transcription and cancer. Nat Rev Cancer. 16:803–810. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yin Y, Morgunova E, Jolma A, Kaasinen E,
Sahu B, Khund-Sayeed S, Das PK, Kivioja T, Dave K, Zhong F, et al:
Impact of cytosine methylation on DNA binding specificities of
human transcription factors. Science. 356:eaaj22392017. View Article : Google Scholar : PubMed/NCBI
|
